tbuckley/cabot-search huggingface dataset:
Combined epigenetic signature and gene copy number variations in IDH-mutant glioblastomas showed varied risk stratification
Authors: Ho Keung Ng, Kay Ka-Wai Li, Tathiane M Malta, Zhi-feng Shi, Houtan Noushmehr
Journal: Neuro-Oncology (2019)

Abstract The number of IDH-mutant glioblastoma examined in the literature and TCGA is few. We used Infinium MethylationEPIC BeadChip array to classify 64 IDH-mutant-GBM into methylation groups. Gene copy number variations were determined from methylation. 53.1%, 35.9%, and 10.9% of tumors belonged to G-CIMP-high, G-CIMP-low and codel groups respectively. G-CIMP-low group of IDH-mutant glioblastoma was associated with worse survival as compared to G-CIMP-high (p=0.005) and Codel groups (p=0.009). CDKN2A deletion (24/64; 37.5%) was the most common gene copy number variation, and was significantly associated with GCIMP-low subgroup (p=0.001). Amplification of MET was identified in 3/64 (9.4%), CCND2 11/64 (17.2%), PDGFRA 9/64 (14.1%), CDK4 8/64 (12.5%) and EGFR 8/64 cases (12.5%). Both CDKN2A deletion (p=0.008) and MET amplification (p&lt;0.001) were associated with poor survival. Combined methylation signature and gene copy number variations separated IDH-mutant glioblastoma into Group 1 (codeleted), Group 2 (GCIMP-high without CDKN2A deletion), Group 3 (GCIMP-high with CDKN2A deletion), Group 4 (GCIMP-low without CDKN2A and MET alterations), and Group 5 (GCIMP-low with CDKN2A and/or MET alterations). Group 1 had a favorable overall survival with a median survival of 1240 days. Groups 2, 3, and 4 exhibited an intermediate outcome with a median survival of 536, 619, and 655 days respectively. Group 5 exhibited a poor outcome with a median survival of 255 days. Groups based on combined methylation signature and CDKN2A/MET status are an independent prognostic factor. Conclusion: IDH mutant glioblastomas should be stratified for risk with combined epigenetic signature and CDKN2A/MET status and some cases have unfavorable outcomes.
All-Trans Retinoic Acid (ATRA) Targets IRF4 Deficient, NOTCH2-Activated B Cells from Chronic Gvhd Patients
Authors: Jonathan C. Poe, Wei Jia, Hsuan Su, Zhiguo Li, Frances T. Hakim, Steven Z. Pavletic, Jeremy J. Rose, David A Rizzieri, Yiping Yang, Benny J. Chen, Sarah Anand, Jerome Ritz, Christian W. Siebel, Nelson J. Chao, Ivan Maillard, Stefanie Sarantopoulos
Journal: Blood (2016)
A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial
Authors: Daniel J. DeAngelo, Kristen Stevenson, Donna S Neuberg, Lewis B. Silverman, Karen K. Ballen, Julie D. Asch, Yasser Abou Mourad, Kristjan Paulson, Matthew D. Seftel, David Avigan, Julie Bergeron, Stephen Couban, William Blum, John Storring, Martha Wadleigh, David P. Steensma, Jeffrey Supko, Stephen E. Sallan, Richard M. Stone
Journal: Blood (2015)
Alternative Donor Transplantation For Adults With Lymphoma: Comparison Of Umbilical Cord Blood Versus 8/8 HLA-Matched Donor (URD) Versus 7/8 URD
Authors: Veronika Bachanova, Claudio Brunstein, Linda J. Burns, Tao Wang, Jeanette Carreras, Ginna G. Laport, Sonali M. Smith, Silvia Montoto, David G. Maloney, Wael Saber
Journal: Blood (2013)
Phase I Study of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
Authors: Dai Chihara, Yasuhiro Oki, Luis Fayad, Emily Wesson, Charnelle Ruben, Sandra B Horowitz, Joseph Woolery, Lei Feng, Naveen Garg, Sairah Ahmed, Issa F. Khouri, Michelle A. Fanale
Journal: Blood (2014)
Hyperphosphorylated Paratarg-7 Is a Frequent Antigenic Target of IgM Paraproteins, Is Dominantly Inherited and Represents a Highly Significant Risk Factor for Monoclonal Gammopathy of Undetermined Significance of the IgM Type (IgM-MGUS) and Waldenstrom's Macroglobulinemia (WM), Allowing for the Identification of Family Members at Risk in Cases of Familial IgM-MGUS and WM.
Authors: Sandra Grass, Klaus-Dieter Preuss, Alexandra Wikowicz, Evangelos Terpos, Marita Ziepert, Manfred Ahlgrimm, Natalie Fadle, Evi Regitz, Niels Murawski, Meletios A. Dimopoulos, Steven P. Treon, Zachary Hunter, Michael Pfreundschuh
Journal: Blood (2009)
Demethylating Agents Reprogram Myelodysplastic Syndrome and Leukemia Cells, Sensitizing Them To Poly-(ADP)-Ribose Polymerase Inhibitors
Authors: Carine Robert, Nidal E Muvarak, Vu H. Duong, Maria R. Baer, Stephen B. Baylin, Feyruz Rassool
Journal: Blood (2013)
Postoperative and Nonvalvular Atrial Fibrillation—Not So Different After All
Authors: Jonathan P. Piccini
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Potency and Selectivity Assessment of Small Molecules Against Janus Kinase (JAK) 2: Widely Used AG490 Inhibitor Is Neither Potent Nor Selective for JAK2
Authors: Angus Sinclair, Ivonne Archibeque, Jinghui Zhan, Liqin Liu, Renee Emkey, Elizabeth Doherty, C. Glenn Begley
Journal: Blood (2011)
Liquefied Microcapsules as Dual‐Microcarriers for 3D+3D Bottom‐Up Tissue Engineering
Authors: Clara R. Correia, Isabel M. Bjørge, Jinfeng Zeng, Michiya Matsusaki, João F. Mano
Journal: Advanced Healthcare Materials (2019)

Abstract Cell encapsulation systems must ensure the diffusion of molecules to avoid the formation of necrotic cores. The architectural design of hydrogels, the gold standard tissue engineering strategy, is thus limited to a microsize range. To overcome such a limitation, liquefied microcapsules encapsulating cells and microparticles are proposed. Microcapsules with controlled sizes with average diameters of 608.5 ± 122.3 µm are produced at high rates by electrohydrodynamic atomization, and arginyl–glycyl–aspartic acid (RGD) domains are introduced in the multilayered membrane. While cells and microparticles interact toward the production of confined microaggregates, on the outside cell‐mediated macroaggregates are formed due to the aggregation of microcapsules. The concept of simultaneous aggregation is herein termed as 3D+3D bottom‐up tissue engineering. Microcapsules are cultured alone (microcapsule 1 ) or on top of 2D cell beds composed of human umbilical vein endothelial cells (HUVECs) alone (microcapsule 2 ) or cocultured with fibroblasts (microcapsule 3 ). Microcapsules are able to support cell encapsulation shown by LiveDead, 3‐(4,5‐dimethylthiazol‐2‐yl)‐5‐(3‐carboxymethoxyphenyl)‐2‐(4‐sulphofenyl)‐2 H ‐tetrazolium (MTS), and dsDNA assays. Only microcapsule 3 are able to form macroaggregates, as shown by F‐actin immunofluorescence. The bioactive 3D system also presented alkaline phosphatase activity, thus allowing osteogenic differentiation. Upon implantation using the chick chorioallontoic membrane (CAM) model, microcapsules recruit a similar number of vessels with alike geometric parameters in comparison with CAMs supplemented with basic fibroblast growth factor (bFGF).
Umbilical Cord Blood CD133+ Stem Cells Exhibit Vasculogenic Capacity In Vitro and Augment Neovasculogenesis In Vivo in a Murine Model of Vascular Ischemia.
Authors: M.R. Finney, L.R. Fanning, P.J. Vincent, D.G. Winter, M.A. Hoffman, K.J. Antepara, N.J. Greco, M. Kozik, M.E. Joseph, P. Fu, Mary J. Laughlin
Journal: Blood (2006)
Dasatinib Cerebrospinal Fluid Concentration and Plasma Pharmacokinetics: Potential for Central Nervous System Prophylaxis In Philadelphia Chromosome-Positive Leukemia
Authors: Naoto Takahashi, Masatomo Miura, Stuart Scott, Hirobumi Saitoh, Mutsuhito Motegi, Naohito Fujishima, Yoshihiro Kameoka, Hiroyuki Tagawa, Makoto Hirokawa, Kenichi Sawada
Journal: Blood (2010)
Mitogen Stimulated Direct Antiglobulin Test Compared with Traditional Methods for the Detection of Anti-RBC Autoimmunity.
Authors: Wilma Barcellini, Nicoletta Revelli, Francesca Guia Imperiali, Maria Antonietta Villa, Maria Cristina Manera, Cinzia Paccapelo, Anna Zaninoni, Alberto Zanella
Journal: Blood (2009)
Influence of financial conditions on stress in colorectal cancer patients undergoing outpatient chemotherapy
Authors: Yukiko Tatsumi, Harue Arao, Akiko Hatakeyama, Youko Minamiguchi, Masayo Toki, Naomi Fujikawa, Kouta Asano, Ayumi Takao, Miwa Aoki
Journal: Annals of Oncology (2019)
Management of Chronic Myeloid Leukemia in Children and Adolescents According to Local Guidelines.the Italian Experience
Authors: Fiorina Giona, Michelina Santopietro, Giuseppe Menna, Maria Caterina Putti, Concetta Micalizzi, Nicola Santoro, Ottavio Ziino, Rosamaria Mura, Saverio Ladogana, Grazia Iaria, Antonella Sau, Roberta Burnelli, Nadia Vacca, Margherita Nardi, Caterina Consarino, Maria Luisa Moleti, Mauro Nanni, Daniela Diverio, Anna Leszl, Andrea Biondi, Franco Locatelli, Giuseppe Saglio, Robin Foà
Journal: Blood (2016)
Hepatic Rab24 controls blood glucose homeostasis via improving mitochondrial plasticity
Authors: Susanne Seitz, Yun Kwon, Götz Hartleben, Julia Jülg, Revathi Sekar, Natalie Krahmer, Bahar Najafi, Anne Loft, Sofiya Gancheva, Kerstin Stemmer, Annette Feuchtinger, Martin Hrabe de Angelis, Timo D. Müller, Matthias Mann, Matthias Blüher, Michael Roden, Mauricio Berriel Diaz, Christian Behrends, Jerome Gilleron, Stephan Herzig, Anja Zeigerer
Journal: Nature Metabolism (2019)
Evaluation of Conflicts of Interest in Basic Science Studies Evaluating Erythropoietin and Erythropoietin Effects of Solid Cancer Cell Lines
Authors: Sara E Barnato, Simone N Boyle, Adam Kuykendal, Stephen Y Lai, Robin L Wagner, Carolyn E Goldstein, Athena T Samaras, Dennis P West, Jacob Tallman, Michael Henke, A. Oliver Sartor, Charles L. Bennett
Journal: Blood (2008)
A Truncation Mutant of CSF3R, Identified As a Novel Driver in De Novo Myeloid Leukemia, Signals Through TNK2, and Is Responsive to Dasatinib.
Authors: Julia E Maxson, Jason Gotlib, Angela G. Fleischman, Christopher A. Eide, Daniel Bottomly, Beth Wilmot, Shannon McWeeney, Cristina Tognon, Marc M Loriaux, Brian J. Druker, Jeffrey W Tyner
Journal: Blood (2012)
Monitoring ADAMTS13 Autoantibody Titer Using a Novel Quantitative Radioimmunoprecipitation Assay In Patients With Acquired Thrombotic Thrombocytopenic Purpura
Authors: Atsuko Igari, Takanori Moriki, Hideo Wada, Kenji Soejima, Mitsuru Murata
Journal: Blood (2013)
Hodgkin Lymphoma in Older Patients- a Retrospective Analysis of the Polish Lyphoma Reasearch Group
Authors: Tomasz Wrobel, Olga Dobrzynska, Ewa Chmielowska, Elzbieta Nowara, Agnieszka Badora-Rybicka, Anna Szulgo, Natalia Sorbotten, Wojciech Jurczak, Giza Agnieszka, Krzysztof Adamowicz, Agata Bartoszko, Krzysztof Lesniewski-Kmak, Wanda Knopinska-Posluszny, Waldemar Kulikowski, Renata Kroll, Andrzej Balcerzak, Wojciech Spychalowicz, Ewa Kalinka-Warzocha, Beata Kumiega, Joanna E Drozd-Sokolowska, Edyta Subocz, Agata Salek, Jadwiga Holojda, Joanna Pogrzeba, Jaroslaw Dybko, Rafal Poreba, Jan Maciej Zaucha
Journal: Blood (2014)
Late Appearance of 14q32/IGH Translocation in Chronic Lumphocytic Leukemia
Authors: Francesco Cavazzini, Gian Matteo Rigolin, Lara Rizzotto, Antonella Bardi, Elisa Tammiso, Elisa Pezzolo, Eleonora Volta, Dalila De Pasquale, Melissa Dabusti, Elena Saccenti, Maria Ciccone, Lydia Scarfò, Francesca Cibien, Olga Sofritti, Giulia Daghia, Sara Martinelli, Antonio Cuneo
Journal: Blood (2010)
A Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week Epoetin Alfa and Every-3-Week Darbepoetin Alfa: A Study of the Mayo Clinic Cancer Research Consortium (MCCRC).
Authors: David P Steensma, Shaker R. Dakhil, Paul J Novotny, Jeff A Sloan, David B Johnson, Daniel M Anderson, Bassam I Mattar, Dennis F Moore, Daniel Nikcevich, Charles L Loprinzi
Journal: Blood (2009)
Apoptosis in Chronic Myeloid Leukemia Cells Transiently Treated with Imatinib or Dasatinib Is Caused by Residual BCR-ABL Kinase Inhibition
Authors: Pavel Simara, Stanislav Stejskal, Irena Koutna, David Potesil, Lenka Tesarova, Michaela Potesilova, Zbynek Zdrahal, Jiri Mayer
Journal: Blood (2012)
Prognostic Value of Positron Emission Tomography (PET) Scan in Patients with Relapsed Hodgkin Lymphoma or Aggressive Non-Hodgkin Lymphoma Receiving Salvage Chemotherapy Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation.
Authors: Anna Dodero, Roberto Crocchiolo, Francesca Patriarca, Fabio Ciceri, Nicolo’ Frungillo, Roberto Fanin, Rosalba Miceli, Andrea Assanelli, Raffaella Milani, Flavio Crippa, Paolo Corradini
Journal: Blood (2007)
Pegylated Interferon-Alfa-2a In Clinical Responders Often Decreases JAK2 V617F Allelic Burden and/or Reverses Clonal Hematopoiesis, but These Are Not Always Parallel In PV and ET Females
Authors: Sabina Swierczek, Srdan Verstovsek, Archana Agarwal, Taghi Manshouri, Kimberly Hickman, Josef T. Prchal
Journal: Blood (2010)
Interference of HMGB1 Lead to Increased Vulnerability of MM Cells to Dexamethasone and Doxorubicin
Authors: Xing Guo, Donghua He, Jing Chen, Xuanru Lin, Qingxiao Chen, Haimeng Yan, Xi Huang, Yi Li, Li Yang, Enfan Zhang, Yang Yang, Wenjun Wu, Jingsong He, He Huang, Zhen Cai
Journal: Blood (2016)
What Is Allergic Bronchopulmonary Aspergillosis (ABPA)?
Journal: American Journal of Respiratory and Critical Care Medicine (2014)

What is Aspergillus?Aspergillus is a type of fungus (also referred to as a mold), that is commonly found in the environment.It can be found in the soil, dust, water, and rotting or decaying vegetation (like dead leaves or compost piles), marijuana, and some foods and ground spices.The fungus forms into spores which are very small particles that can float in the air.Most people inhale its spores from the air, but do not have any problems from being exposed.In most cases, the fungus can live in the mucus in the breathing tubes (airways).This is called colonization.Having Aspergillus in your airways does not mean you have or will have a sudden (acute), and serious infection by this fungus.Our immune system usually helps protect the body from infections like these.In some people who have a weakened immune system, Aspergillus can get into the lungs, causing an acute infection.(For more about Aspergillus infection, see the ATS Patient Information Series fact sheet: Aspergillosis in the Fungal Disease Series).However, in a few cases, this exposure to Aspergillus triggers an allergic immune response without invading the tissues that leads to ABPA (allergic bronchopulmonary aspergillosis).
Cytogenetic Heterogeneity in Clonal Plasma Cell Disorders: A Study in Highly Purified Aberrant Plasma Cells
Authors: Martin Schmidt-Hieber, María Laura Gutiérrez, Martin Perez-Andres, Bruno Paiva, Ana Rasillo, Maria Dolores Tabernero, José Maria Sayagués, Antonio Lopez, Paloma Barcena, Maria Luz Sanchez, Norma Gutierrez, Jesus F San Miguel, Alberto Orfao
Journal: Blood (2012)
Severe Telomeric Erosion In Ph-Negative Hematopoiesis After Successful CML Treatment: Association with Acquired Cytogenetic Lesions and Hematological Toxicity.
Authors: Chiara Lobetti Bodoni, Ferrero Dario, Elisa Genuardi, Roberto Passera, Elisa Bernocco, Sia Daniela, Elena Crisà, Giovanni Grignani, Alberto Rocci, Luigia Monitillo, Daniela Drandi, Valentina Giai, Simone Ferrero, Michela Boi, Elisabetta Mantella, Gianluca Isaia, Monia Lunghi, Elisabetta Abruzzese, Franca Radaelli, Massimo Pini, Patrizia Pregno, Carmelo Carlo-Stella, Gianluca Gaidano, Mario Boccadoro, Marco Ladetto
Journal: Blood (2010)
A Low Concentration of ABL001 Potentiates In Vitro TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells
Authors: Verity A Saunders, Jueqiong Wang, Liu Lu, Laura N Eadie, Jennifer A McLean, Jarrad M Goyne, David T. Yeung, Deborah L White, Timothy P Hughes
Journal: Blood (2016)
Feasibility of a Smartphone-Based Health Coaching Intervention for Patient Self-Management of Nutrition in the Post-Chemotherapy Setting
Authors: Connie E Chen, Alice Y Mao, Jontrice G Murray, Betul Oran, Muzaffar H. Qazilbash, Nina Shah, Sairah Ahmed, Qaiser Bashir, Chitra Hosing, Elizabeth J. Shpall, Joseph R Steele, Richard E. Champlin, Simrit Parmar
Journal: Blood (2016)
Clinical Heterogeneity in RUNX1-Associated Familial Myelodysplastic Syndrome - Report of Two Novel Pedigrees with Childhoodleukemia
Authors: Tim Ripperger, Birgit Burkhardt, Fabian Hauck, Michael H. Albert, Kathrin Thomay, Marcin Wlodarski, Ayami Yoshimi, Gudrun Göhring, Brigitte Schlegelberger, Charlotte M Niemeyer, Doris Steinemann
Journal: Blood (2016)
Synergy Between Kit Ligand (KL) and IL-4 In Mast Cells Is Mediated by Cross-Receptor Interactions In Lipid Rafts.
Authors: Maheswaran Mani, Shivkumar Venkatasubrahmanyam, Yujun Yang, Mark Krampf, Jing Huang, Atul Butte, Thomas Jahn, Kenneth I. Weinberg
Journal: Blood (2010)
Concurrent Visualization of Trafficking and NFAT Signalling in Primary T Lymphocytes and T Cell Precursors In Vivo.
Authors: Il-Kang Na, John Markley, Jennifer Tsai, Nury L. Yim, Bradley J. Beattie, Alexander D. Klose, Amanda M. Holland, Arnab Ghosh, Uttam K. Rao, Matthias Stephan, Inna Serganova, Renier J. Brentjens, Ron R.G. Blasberg, Michel W Sadelain, Marcel R.M. van den Brink
Journal: Blood (2009)
Epstein-Barr Virus Viral Loads and Serum Free Light Chains Levels Are Diagnostic Markers of Lymphoma in HIV-Infected Patients
Authors: Maria Joao Baptista, Mireia Morgades, Agueda Hernandez, Albert Briega, Eva Martinez, Javier Martinez-Picado, Guillem Sirera, Gustavo Tapia, Miriam Moreno, Juan-Manuel Sancho, Evarist Feliu, Josep-Maria Ribera, Jose-Tomas Navarro
Journal: Blood (2014)
Prior Use of Mogamulizumab to Allogenic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-Versus-Host Disease
Authors: Takeshi Sugio, Koji Kato, Takatoshi Aoki, Takanori Ota, Noriyuki Saito, Shuro Yoshida, Ichiro Kawano, Hideho Henzan, Ken Takase, Tsuyoshi Muta, Kohta Miyawaki, Takahiro Shima, Shuichiro Takashima, Takuji Yamauchi, Yasuo Mori, Goichi Yoshimoto, Kenjiro Kamezaki, Katsuto Takenaka, Tomohiko Kamimura, Yuju Ohno, Tetsuya Eto, Ryosuke Ogawa, Hiromi Iwasaki, Toshihiro Miyamoto, Koichi Akashi
Journal: Blood (2015)
The Outcome of Low-Risk Childhood B-Cell Precursor ALL Treated with the Japan Association of Childhood Leukemia Study (JACLS) ALL-02 Trial
Authors: Yoshihiro Takahashi, Toshihiko Imamura, Ikuya Usami, Keiko Yumura-Yagi, Soichi Suenobu, Daiichiro Hasegawa, Shinichiro Nishimura, Nobuhiro Suzuki, Yoshiko Hashii, Takao Deguchi, Akiko M. Saito, Yoshihiro Komada, Yoshiyuki Kosaka, Koji Kato, Ryoji Kobayashi, Hirohide Kawasaki, Hiroki Hori, Atsushi Sato, Tooru Kudo, Tatsutoshi Nakahata, Megumi Oda, Junichi Hara, Keizo Horibe
Journal: Blood (2016)
Wnt Pathway Is Upregulated in Blood Cells From Patients with Paroxysmal Nocturnal Hemoglobinuria.
Authors: Yoshiko Murakami, Norimitsu Inoue, Tsutomu Shichishima, Hideyoshi Noji, Jun-ichi Nishimura, Yuzuru Kanakura, Taroh Kinoshita
Journal: Blood (2009)
Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non- Hodgkin’s Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study
Authors: Marinus H.J. Van Oers, Martine Van Glabbeke, Liliana Baila, Livia Giurgia, Richard Klasa, Robert E Marcus, Max Wolf, Eva Kimby, Anton Hagenbeek
Journal: Blood (2008)
Correlation of progression-free survival at 6 months (PFS6) with overall survival at 12 months (OS12) in an analysis of 10 trials of second-line therapy for advanced urothelial carcinoma (UC).
Authors: Benjamin Maughan, Kenneth M. Boucher, Neeraj Agarwal, Toni K. Choueiri, Angela Q. Qu, Nicholas J. Vogelzang, Ronan Fougeray, Guenter Niegisch, Peter Albers, Yu-Ning Wong, Yoo-Joung Ko, Srikala S. Sridhar, Matt D. Galsky, Daniel Peter Petrylak, Ulka N. Vaishampayan, Tomasz M. Beer, Cora N. Sternberg, Jonathan E. Rosenberg, Joaquim Bellmunt Molins, Guru Sonpavde
Journal: Journal of Clinical Oncology (2012)

4525 Background: Second-line therapy of advanced UC is a significant unmet need. While phase II trials have relied on response rate (RR) as a primary endpoint, response may not be suitable for assessing cytostatic agents and does not capture duration of benefit. We hypothesized that PFS6 correlates with OS12 and may be a robust intermediate endpoint for phase II trials. Methods: Ten trials with individual patient progression and survival data (n=646) evaluating chemotherapy and/or biologics following chemotherapy were combined. Progression was defined as tumor progression (RECIST 1.0 in 9 trials, WHO in 1 trial), or death from any cause. Unadjusted and adjusted binomial confidence intervals for PFS6, OS12 and response were reported, with adjustment for variability between trials using random effects models. The relationship between PFS6 and OS12 was assessed at the trial level using Pearson correlation and weighted linear regression with larger studies having more influence. The relationship between PFS6 and OS12 at the individual level was assessed using Pearson chi-square test with Yates continuity correction. Statistical analyses employed “R” statistical computing software, version 2.8.0. Results: 59% had visceral metastasis and performance status was 0, 1 and 2 in 50, 39 and 8%, respectively. Median age was 65 years (31-88) and 77% were male. PFS6 was 22% (95% CI: 17-24%), and adjusted PFS6 was 23% (95% CI: 15-34%). The OS12 was 20% (95% CI: 17-24%), and adjusted OS12 was 21% (95% CI: 15-29%). The Pearson correlation between trial level PFS6 and OS12 was 0.66 (p = 0.037). The individual level agreement between PFS6 and OS12 was seen in 82% of patients (kappa = 0.45). Among 560 patients evaluable for response and OS, the RR was 22% (95% CI: 18-25%) and adjusted RR was 21% (95% CI: 13-32%). Trial level Pearson correlation between response and OS12 was 0.37 (p = 0.30), and individual level agreement was seen in 78% (kappa=0.36). Conclusions: PFS6 is associated with OS12 at the trial and individual levels in patients receiving second-line therapy for advanced UC. The association of response with OS was suboptimal. Validation of PFS6 is warranted.
Immunoglobulin Heavy Chain Locus (IGH@) Translocations in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Incidence and Risk Stratification
Authors: Lisa J Russell, Lisa Jones, Amy Erhorn, Amir Ensahei, Dino Masic, Helen Bentley, Karl S Laczko, Christine J Harrison
Journal: Blood (2012)
A Novel Antibody-Based Minimal Intensity Conditioning Regimen for Children with Severe Organ Toxicity or DNA Repair Disorders.
Authors: K.C. Straathof, K. Rao, G. Hale, P. Bird, E. Perry, E.G. Davies, M.K. Brenner, P.A. Veys, Persis J. Amrolia
Journal: Blood (2007)
Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia
Authors: Michael Boyiadzis, Mounzer Agha, Robert L Redner, Alison Sehgal, Annie Im, Jing-Zhou Hou, Rafic Farah, Kathleen A. Dorritie, Anastasios Raptis, Seah H. Lim, Hans Klingemann, Hong Wang, Natalia Lapteva, Mei Zhuyong, Lisa H Butterfield, Cliona M. Rooney, Theresa L Whiteside
Journal: Blood (2016)
Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Exhibit Altered Cytokine Protein Levels in Peripheral Blood Serum
Authors: Laura A Paganessi, Robin R Frank, Sucheta Jagan, Reem Karmali, Yan Li, Youping Deng, Cristina L Fhied, Jeffrey A Borgia, Melissa L Larson, Parameswaran Venugopal, Stephanie A. Gregory, Kent W Christopherson
Journal: Blood (2011)